가바펜틴 시장 : 전략적 인사이트와 예측(2026-2031년)

The Gabapentin Market is projected to grow from USD 2.4 billion in 2026 to USD 3.0 billion in 2031, reflecting a 4.6% CAGR.

The global gabapentin market operates in a post-patent, generic-dominant paradigm that has fundamentally redefined its commercial dynamics since the expiration of the original Neurontin brand exclusivity. Originally developed as an anticonvulsant for partial seizures, gabapentin has evolved into a high-volume analgesic agent, primarily indicated for neuropathic pain conditions. The widespread availability of low-cost generic formulations has democratized access, shifting market value from high-margin branded revenues to large-scale generic volume throughput. The drug's established efficacy, relatively favorable side effect profile, and wide therapeutic index have cemented its role as a first-line treatment option in chronic pain management. Sustained expansion is now navigated against a backdrop of intensifying regulatory scrutiny, prescribing constraints linked to opioid co-administration risks, and the ongoing challenge of severe price compression across all market segments.

Market Drivers

The escalating global prevalence of chronic neuropathic pain conditions is the foremost demand driver. Postherpetic neuralgia, diabetic peripheral neuropathy, and related nerve damage disorders are highly prevalent in aging and metabolically compromised populations, with nearly a quarter of adults in the United States reporting chronic pain. This large, continuously growing patient pool creates persistent, high-volume demand for effective and accessible pharmacological management. A parallel structural driver is the global de-escalation of opioid prescribing. Government programs and health system initiatives targeting the opioid crisis have directly accelerated clinical substitution toward non-scheduled, non-opioid analgesics, elevating gabapentin as a preferred cost-effective alternative in primary and specialty care settings. The broad availability of generic formulations at accessible price points further lowers the barrier to adoption, enabling penetration across all healthcare tiers, including high-volume public health systems in emerging markets such as Brazil and China.

Market Restraints

Pervasive generic competition constitutes the primary structural constraint, driving sustained price erosion that compresses profit margins for all market participants and limits investment in novel branded development. Regulatory and clinical caution surrounding respiratory depression risk is a secondary headwind, particularly where gabapentin is co-prescribed with opioids or other Central Nervous System (CNS) depressants. The U.S. FDA has mandated updated prescribing warnings to this effect, imposing constraints on a previously common co-prescription pattern. At the payer and policy level, NHS and NICE guidelines in the United Kingdom recommend regular patient review and trial discontinuation for chronic pain indications, dampening long-term prescription volumes to verified clinical need. State-level Prescription Drug Monitoring Programs (PDMPs) in the United States, and controlled substance classifications such as ANVISA's List C1 designation in Brazil, add prescribing friction that moderates demand growth in key regional markets. Supply chain concentration in API manufacturing hubs in India and China introduces geopolitical and logistical vulnerability to the global supply continuity of finished dosage forms.

Technology and Segment Insights

The Neuropathic Pain application segment is the largest and most structurally entrenched demand category, driven by the drug's validated mechanism of binding to the alpha-2-delta subunit of voltage-gated calcium channels to suppress aberrant nerve signaling. The Generic type segment commands the overwhelming majority of market volume, with branded products such as Pfizer's Neurontin and Gralise retaining a narrow foothold limited to specific FDA-approved indications. The principal innovation opportunity lies in extended-release (ER) formulations, which offer improved pharmacokinetic profiles, reduced dosing frequency, and potential for premium pricing in a market otherwise defined by commodity competition. Hospital Pharmacy represents the largest distribution channel, driven by formulary inclusion and high utilization in multimodal analgesia protocols for surgical and inpatient settings, where gabapentin reduces opioid consumption and improves recovery outcomes. In China, provincial-level procurement tenders and the country's role as a dominant global API producer create a structurally unique market dynamic combining high-volume domestic demand with cost-efficient local supply.

Competitive and Strategic Outlook

The competitive environment is defined by volume-driven generic rivalry, where operational efficiency, cost leadership in API sourcing, and supply chain robustness determine market position. Teva Pharmaceuticals leads as a dominant volume supplier, leveraging large-scale manufacturing capacity and pharmacy benefit manager (PBM) contracting strength across multiple dosage forms. Lupin, drawing on vertically integrated API and finished dosage manufacturing in India, competes through regulatory compliance and competitive pricing in heavily regulated markets including the United States. Pfizer retains a legacy presence through its branded portfolio, concentrating on neurologist relationships and specific approved indications, though its revenue contribution from gabapentin is substantially outpaced by generic volume leaders. Notable recent developments include Sunshine Biopharma's June 2025 launch of generic gabapentin capsules across three strengths in Canada, and the 2023 introduction of Gabapentin ER 300/600 mg in South Korea through a collaboration between Lotus Pharmaceutical and Adalvo, reflecting continued international generic expansion into underserved markets.

Conclusion

The gabapentin market is set for steady, volume-driven growth through 2031, underpinned by the rising global burden of neuropathic pain, the structural shift away from opioid-based analgesia, and the sustained accessibility of generic formulations across diverse healthcare systems. Participants that combine cost-efficient API procurement, regulatory compliance strength, and targeted investment in differentiated ER formulations will be best positioned to sustain competitive advantage in an otherwise commoditized market.

Key Benefits of this Report

• Insightful Analysis: Gain detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2025 and forecast data from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Force Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. GABAPENTIN MARKET, BY TYPE

• 5.1. Introduction
• 5.2. Generic
• 5.3. Branded

6. GABAPENTIN MARKET, BY APPLICATION

• 6.1. Introduction
• 6.2. Epilepsy
• 6.3. Neuropathic Pain
• 6.4. Restless Legs Syndrome
• 6.5. Others

7. GABAPENTIN MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Retail Pharmacy
• 7.4. Others

8. GABAPENTIN MARKET, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. The Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Pfizer
• 10.2. Fierce Pharma
• 10.3. Mayo Clinic
• 10.4. Ralington Pharma
• 10.5. Teva Pharmaceuticals
• 10.6. Gralise
• 10.7. Glenmark Pharmaceuticals
• 10.8. Stensa Lifesciences
• 10.9. Rosemont Pharmaceuticals
• 10.10. Lupin